Clinical Trial Update: Dornase Alfa and Cisplatin in Refractory Germ Cell Cancer. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of Dornase alfa and cisplatin for refractory germ cell tumors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Germ Cell Tumor
• Testicular Germ Cell Tumor

Drugs mentioned

• CISPLATIN (cisplatin)
• Dornase alfa (dornase alfa)

Snippet

Sponsor: National Cancer Institute, Slovakia | Conditions: Refractory Germ Cell Tumors, Dornase Alfa | Phase 2 | Status: RECRUITING